Literature DB >> 29417256

Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.

Oliver Königsbrügge1, Günter Weigel2, Peter Quehenberger3, Ingrid Pabinger1, Cihan Ay4.   

Abstract

The effect of direct oral anticoagulants (DOACs) on turbidimetric measurements of plasma clot formation and susceptibility to fibrinolysis may facilitate a comparison between different classes of anticoagulants in plasma samples. We obtained 424 citrate plasma samples from 226 atrial fibrillation patients on anticoagulation and 24 samples without anticoagulation serving as controls. As comparators, we measured the international normalized ratio (INR) for phenprocoumon samples (N = 166), anti-Xa for low molecular weight heparin (LMWH) samples (N = 42), and DOAC levels with mass spectrometry (dabigatran N = 40, rivaroxaban N = 110, apixaban N = 42). Plasma clot formation and lysis were recorded continuously on a photometer after addition of an activation mix (tissue factor 2 pmol/l and tissue plasminogen activator 333 ng/ml). We used linear regression and ANCOVA for correlation analysis. Clot formation lag phase was prolonged in the presence of anticoagulants in a concentration-dependent manner for DOACs (dabigatran Spearman r = 0.74; rivaroxaban r = 0.78; apixaban r = 0.72, all p < 0.0001), INR dependent for phenprocoumon (r = 0.59, p < 0.0001), anti-Xa level dependent in LMWH samples (r = 0.90, p < 0.0001). Maximum rate of clot formation and peak clot turbidity were reduced in the presence of anticoagulants, but correlated only moderately with the comparator measures of anticoagulation. The clot lysis time was inversely correlated with DOAC concentrations in the presence of recombinant thrombomodulin. A direct ex vivo comparison between the effects of different classes of anticoagulants is possible with turbidimetric measurement of plasma clot formation and lysis. Anticoagulation inhibited clot formation in a plasma concentration manner for DOACs, INR dependent for phenprocoumon, and anti-Xa dependent for LMWH. Susceptibility to fibrinolysis increased with increasing DOAC concentrations.

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Coagulation assays; Liquid chromatography–mass spectrometry

Mesh:

Substances:

Year:  2018        PMID: 29417256     DOI: 10.1007/s10238-018-0490-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  27 in total

1.  Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.

Authors:  Mirjam E Meltzer; Ton Lisman; Philip G de Groot; Joost C M Meijers; Saskia le Cessie; Carine J M Doggen; Frits R Rosendaal
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

Review 2.  Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.

Authors:  Ton Lisman
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

3.  Thrombin generation in patients with a bleeding tendency of unknown origin.

Authors:  Cihan Ay; Johanna Haselböck; Clarissa Laczkovics; Silvia Koder; Ingrid Pabinger
Journal:  Ann Hematol       Date:  2011-02-26       Impact factor: 3.673

4.  Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.

Authors:  Oliver Königsbrügge; Peter Quehenberger; Sabine Belik; Günter Weigel; Christoph Seger; Andrea Griesmacher; Ingrid Pabinger; Cihan Ay
Journal:  Ann Hematol       Date:  2015-05-30       Impact factor: 3.673

5.  The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system.

Authors:  L Bajzár; J C Fredenburgh; M Nesheim
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

6.  Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.

Authors:  Michal Ząbczyk; Margareta Blombäck; Jacek Majewski; Grzegorz Karkowski; Hakan N Wallen; Anetta Undas; Shu He
Journal:  Thromb Haemost       Date:  2014-12-18       Impact factor: 5.249

7.  Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.

Authors:  C T Ammollo; F Semeraro; F Incampo; N Semeraro; M Colucci
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

8.  A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples.

Authors:  Christoph Seger; Karin Tentschert; Wolfgang Stöggl; Andrea Griesmacher; Steven L Ramsay
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

9.  Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.

Authors:  J Douxfils; J-M Dogné; F Mullier; B Chatelain; Y Rönquist-Nii; R E Malmström; P Hjemdahl
Journal:  Thromb Haemost       Date:  2013-06-20       Impact factor: 5.249

10.  Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant Therapy.

Authors:  Michal Zabczyk; Krzysztof Plens; Wioletta Wojtowicz; Anetta Undas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-29       Impact factor: 8.311

View more
  8 in total

1.  Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.

Authors:  Piotr Mazur; Jacek Myć; Joanna Natorska; Krzysztof Plens; Dariusz Plicner; Grzegorz Grudzień; Bogusław Kapelak; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

2.  Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.

Authors:  Yoshiyuki Morishima; Chikako Kamisato; Yuko Honda
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

Review 3.  Admission Severity of Atrial-Fibrillation-Related Acute Ischemic Stroke in Patients under Anticoagulation Treatment: A Systematic Review and Meta-Analysis.

Authors:  Catarina Garcia; Marcelo Silva; Mariana Araújo; Mariana Henriques; Marta Margarido; Patrícia Vicente; Hipólito Nzwalo; Ana Macedo
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

Review 4.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

5.  Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation.

Authors:  David J Seiffge; Gian Marco De Marchis; Masatoshi Koga; Maurizio Paciaroni; Duncan Wilson; Manuel Cappellari; Kosmas Macha Md; Georgios Tsivgoulis; Gareth Ambler; Shoji Arihiro; Leo H Bonati; Bruno Bonetti; Bernd Kallmünzer; Keith W Muir; Paolo Bovi; Henrik Gensicke; Manabu Inoue; Stefan Schwab; Shadi Yaghi; Martin M Brown; Philippe Lyrer; Masahito Takagi; Monica Acciarrese; Hans Rolf Jager; Alexandros A Polymeris; Kazunori Toyoda; Michele Venti; Christopher Traenka; Hiroshi Yamagami; Andrea Alberti; Sohei Yoshimura; Valeria Caso; Stefan T Engelter; David J Werring
Journal:  Ann Neurol       Date:  2020-02-12       Impact factor: 10.422

6.  Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors.

Authors:  Julia S Gauer; Nicoletta Riva; Eden M Page; Helen Philippou; Michael Makris; Alex Gatt; Robert A S Ariëns
Journal:  Res Pract Thromb Haemost       Date:  2020-10-25

7.  Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention.

Authors:  Anne-Marije Hulshof; Renske H Olie; Minka J A Vries; Paul W M Verhezen; Paola E J van der Meijden; Hugo Ten Cate; Yvonne M C Henskens
Journal:  Front Cardiovasc Med       Date:  2021-12-22

8.  Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Hui Xia; Ziyao Wang; Min Tian; Zunjing Liu; Zhenhua Zhou
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.